摘要
目的观察并讨论肺癌手术治疗中可必特联合沐舒坦术前雾化吸入的临床疗效。方法选取2013年12月至2016年12月本院90例肺癌患者,将其随机分成研究组与对照组,各45例。对照组术前接受常规生理盐水联合沐舒坦雾化吸入治疗,研究组术前接受可必特联合沐舒坦雾化吸入治疗。观察两组治疗后的术后动脉血气、肺功能、围手术期并发症发生率及细胞计数。结果术后,两组患者的Pa CO2、Pa O2、Sa O2、MVV、FEV1水平比较,差异具有统计学意义(P<0.05);研究组围手术期并发症总发生率明显低于对照组,差异具有统计学意义(P<0.05);两组白细胞计数、中性粒细胞、中性粒细胞绝对值比较,差异具有统计学意义(P<0.05)。结论肺癌患者术前应用可必特联合沐舒坦术前雾化吸入的临床疗效显著,值得临床推广。
Objective To observe and discuss the clinical curative effect of combivent combined with mucosolvan preoperative inhalationin in lung cancer surgery. Methods A total of 90 lung cancer patients underwent lung cancer surgery in our hospital from December 2013 to December 2016 were randomly divided into study group and control group, with45 cases in each group. The control group received conventional saline combined with mucosolvan inhalation before surgery. The study group received combivent combined with mucosolvan preoperative inhalation. The postoperative arterial blood gas, lung function, perioperative complications and cell count were observed in the two groups after treatment. Results The levels of Pa CO2, Pa O2, Sa O2, MVV and FEV1 in the two groups had significant differences(P〈0.05); the incidence of perioperative complications in the study group was significantly less than that in the control group(P〈0.05); the white blood cell count, neutrophil and neutrophil absolute value in the two groups had significant differences( P〈0.05).Conclusion Combivent combined with mucosolvan preoperative inhalation in patients with lung cancer surgery has significant curative effect, which is worthy of promotion.
出处
《临床医学研究与实践》
2018年第3期50-51,共2页
Clinical Research and Practice